Related Experiment Video
Updated: Jul 11, 2026
07:17
Studying Orthodontic Tooth Movement in Mice
Published on: August 2, 2024
Orthodontic tooth movement after different coxib therapies
Felix de Carlos1, Juan Cobo, Carmen Perillan
1Departamento de Cirugia y Especialidades Medico-Quirurgicas, Servicio de Ortodoncia, Universidad de Oviedo, C/Catedrático José Serrano, 33006 Oviedo, Spain. fcarlos@uniovi.es
European Journal of Orthodontics
|September 20, 2007
Summary
Selective cyclooxygenase-2 inhibitors like Celecoxib and Parecoxib can manage orthodontic pain without hindering tooth movement. Rofecoxib, however, significantly slowed dental movement in rats.
Area of Science:
- Biomedical Science
- Pharmacology
- Orthodontics
Background:
- Pain and discomfort are common during orthodontic treatment (OT).
- Conventional non-steroidal anti-inflammatory drugs (NSAIDs) may impede orthodontic tooth movement.
- Selective cyclooxygenase-2 (COX-2) inhibitors offer an alternative for pain management.
Purpose of the Study:
- To compare the effects of different COX-2 inhibitors (Rofecoxib, Celecoxib, Parecoxib) on orthodontic tooth movement in a rat model.
- To determine if these selective COX-2 inhibitors interfere with the biological processes of tooth movement.
Main Methods:
- Twenty-eight Wistar rats were divided into four groups: Rofecoxib, Celecoxib, Parecoxib, and saline control.
- Orthodontic tooth movement was induced using coil springs.
- Selective COX-2 inhibitors or saline were administered via gingival injections over 5 days.
- Tooth movement was quantified using lateral cranial teleradiographs after 10 days.
Main Results:
- Control rats exhibited mesial tooth displacement of 0.33 ± 0.07 mm.
- Rofecoxib treatment resulted in no measurable tooth movement.
- Celecoxib and Parecoxib groups showed tooth movement of 0.42 ± 0.09 mm and 0.22 ± 0.04 mm, respectively.
- Statistical analysis revealed significant differences between groups (P < 0.004).
Conclusions:
- Celecoxib and Parecoxib appear to be suitable for managing orthodontic pain without compromising tooth movement.
- Rofecoxib demonstrated an inhibitory effect on orthodontic tooth movement.
- Selective COX-2 inhibitors have differential effects on orthodontic treatment efficacy.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...